Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2026-03-13
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical CompanyORMP — Oramed Pharmaceuticals Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
$3.85+26.85%Market cap139.31M
- Latest Close
- $3.85
- 30-Day Move
- +26.9%
- Market Cap
- $139M
- Shares Outstanding
- 39,800,000
- P/E Ratio
- 3.11
- P/B Ratio
- 0.67
Analyst consensus: Sell · 6 analysts
NASDAQ:ORMPPharmaceuticals / PharmaceuticalsDelayed public snapshot
Oramed Pharmaceuticals Inc
A read-only Alphactor snapshot forOramed Pharmaceuticals Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$3.85
30-Day Move
+26.9%
Market Cap
$139M
Shares Outstanding
39,800,000
P/E Ratio
3.11
P/B Ratio
0.67
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$3.85
+26.9%last 90 delayed daily bars
Market cap$139M
90D High
$3.96
90D Low
$2.75
Avg Volume
186,894
What stands out
Gross margin is running at 65.0%, which gives a quick read on operating quality before you open the full model.
Net margin is -382.1%, useful for comparing ORMP against peers in Pharmaceuticals.
ORMP is up 26.9% over the last 30 trading days shown on this page.
Latest operating income is $-6M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$1.38
Rule of 40
-837.7%
Fundamentals snapshot
Latest Close
$3.85
30-Day Move
+26.9%
Market Cap
$139M
Shares Outstanding
39,800,000
P/E Ratio
3.11
P/B Ratio
0.67
ROE
-13.0%
ROA
-12.3%
Gross Margin
65.0%
Operating Margin
-225.0%
Net Margin
-382.1%
Debt / Equity
0
Current Ratio
25.19
Dividend Yield
0.0%
Latest Revenue
$0
Financial statement snapshot
Revenue
$0
Gross Profit
$0
Operating Income
$-6M
Net Income
$10M
Gross Margin
65.0%
Net Margin
-38210.0%
Current Ratio
25.19
Debt / Equity
0.00
Valuation snapshot
Fair Value
$1.38
Upside / Downside
-64.2%
Signal
Overvalued
Implied Growth
--
EV/Rev
$1.38
Growth Assumption
-9.6%
Discount Rate
10.5%
Terminal Growth
2.0%
Base FCF
--
Valuation spread
Current Price
$3.85
Composite Fair Value
$1.38
EV/Rev
$1.38
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative FCF — company is cash-flow negative. Reverse DCF requires positive cash flows.
Quality snapshot
Altman Z
2.32
Grey
Piotroski
3
Weak (0-3)
Cash Conversion
-0.14x
Rule of 40
-837.7%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $3M | $-41M | $-37M | $-28M |
| 2023-12-31 | $1M | $-16M | $6M | $-11M |
| 2024-12-31 | $0 | $-13M | $-19M | $-8M |
| 2025-12-31 | $2M | $-15M | $64M | $-11M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2026-01-07
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend PaymentsPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2025-11-17
ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTSPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2025-02-11
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral InsulinPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2024-02-02
Top 4 Health Care Stocks That May Crash This QuarterAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-30 | KIDRON NADAV | F | 44,818 | $3.31 |
| 2026-03-30 | Kidron Miriam | F | 435,084 | $3.31 |
| 2026-03-17 | Kidron Miriam | A | 119,558 | $0.00 |
| 2026-03-17 | KIDRON NADAV | A | 167,005 | $0.00 |
| 2026-03-17 | Hexter Joshua | A | 95,889 | $0.00 |
| 2026-03-17 | Gabay Avraham | A | 95,889 | $0.00 |
| 2026-03-12 | KIDRON NADAV | G | 100,000 | $0.00 |
| 2026-01-22 | KIDRON NADAV | M | 109,000 | $0.00 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| iShares Trust-iShares Micro-Cap ETF | 92,854 | 0.00% | 2026-01-31 |
| Dimensional ETF Trust-Dimensional US Core Equity 2 ETF | 36,536 | 0.00% | 2026-01-31 |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Core Equity 2 Portfolio | 23,349 | 0.00% | 2026-01-31 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 24,282 | 0.00% | 2026-02-28 |
| American Century ETF Trust-Avantis U.S. Small Cap Equity ETF | 20,049 | 0.00% | 2026-02-28 |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Small Cap Portfolio | 12,774 | 0.00% | 2026-01-31 |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Vector Equity Portfolio | 10,581 | 0.00% | 2026-01-31 |
| EQ Advisors Trust-1290 VT Micro Cap Portfolio | 7,025 | 0.00% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Two Sigma Advisers
Filed 2025-08-14
--
--
Marshall Wace
Filed 2026-02-13
$738,308
--
Citadel Advisors
Filed 2026-02-17
$558,657
--
Renaissance Technologies
Filed 2026-02-12
$420,375
-0.9%
BlackRock
Filed 2024-05-10
$260,741
--
Analyst consensus?
Rating(?)
2.17
Consensus
SellTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
6
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.